<DOC>
	<DOCNO>NCT00465647</DOCNO>
	<brief_summary>The primary objective study characterize pharmacokinetics pharmacodynamics hydromorphone oral solution pediatric subject age 28 day 16 year inclusive . The secondary objective characterize safety efficacy hydromorphone oral solution pediatric subject age 28 day 16 year inclusive .</brief_summary>
	<brief_title>An Open-label Study Hydromorphone Oral Solution Subjects Aged 28 Days 16 Years Postoperative Pain</brief_title>
	<detailed_description>Hydromorphone opioid analgesic use decade alternative morphine treatment moderate severe malignant nonmalignant pain . Only small number analgesic study child . The benefit subject include contribution knowledge provide appropriate dose regimen recommendation future pediatric subject . Treatment consist parenteral oral hydromorphone . For 48 hour immediately follow surgery , subject administer hydromorphone IV PCA pump . Dosing oral hydromorphone HCl begin subject ready take clear oral liquid . Subjects administer oral hydromorphone HCl every 6 hour 9 dos . The investigator determine time first dose base subject 's clinical condition . The duration treatment phase 102 hour ( 48 hour Parenteral Treatment Period 54 hour Oral Treatment Period ) . Efficacy base oral hydromorphone treatment . Adverse event collect oral parenteral treatment .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>Pediatric subject age 28 day 16 year , Prospective subject anticipate postoperative pain require oral opioid analgesic least 24 hour ( 48 hour ) follow postoperative parenteral analgesia ( 48 hour ) , Prospective subject receive total 7 dos opioids 30 day prior surgery . Prospective subject clinically significant hepatic renal dysfunction impair cardiac and/or respiratory reserve , Prospective subject receive opioid analgesic therapy hydromorphone morphine sulfate 48hour postoperative period prior administration first dose oral hydromorphone , Prospective subject receive regional anesthetic blockade OR analgesic treatment nonopioid medication within 6 hour prior administration first dose oral hydromorphone . Other protocolspecific inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Postoperative pain</keyword>
	<keyword>Hydromorphone oral solution</keyword>
	<keyword>opioid</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>